Trade Savara - SVRA CFD

Add to favourite

4.77

3.05%

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow

Trading сonditions

Spread

0.07

Long position overnight fee

-0.026179%

Short position overnight fee

0.003957%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

USD

Margin

Stock exchange

United States of America

Commission on trade

*Information provided by Capital.com

Savara Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats

Prev. Close*	4.92
Open*	4.85
1-Year Change*	180.35%
Day's Range*	4.77 - 4.96
52 wk Range	1.63-4.97
Average Volume (10 days)	694.78K
Average Volume (3 months)	15.87M
Market Cap	577.91M
P/E Ratio	-100.00K
Shares Outstanding	135.34M
Revenue	N/A
EPS	-0.31
Dividend (Yield %)	N/A
Beta	0.78
Next Earnings Date	Mar 28, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 18, 2024	4.77	-0.13	-2.65%	4.90	4.96	4.75
Apr 17, 2024	4.92	-0.21	-4.09%	5.13	5.16	4.89
Apr 16, 2024	5.11	0.17	3.44%	4.94	5.26	4.81
Apr 15, 2024	5.01	0.04	0.80%	4.97	5.10	4.85
Apr 12, 2024	5.03	-0.25	-4.73%	5.28	5.28	4.96
Apr 11, 2024	5.29	0.56	11.84%	4.73	5.29	4.73
Apr 10, 2024	4.69	0.02	0.43%	4.67	4.77	4.65
Apr 9, 2024	4.86	0.25	5.42%	4.61	4.89	4.58
Apr 8, 2024	4.65	-0.09	-1.90%	4.74	4.75	4.62
Apr 5, 2024	4.74	0.21	4.64%	4.53	4.78	4.49
Apr 4, 2024	4.57	-0.21	-4.39%	4.78	4.81	4.56
Apr 3, 2024	4.74	0.12	2.60%	4.62	4.78	4.57
Apr 2, 2024	4.63	-0.12	-2.53%	4.75	4.75	4.59
Apr 1, 2024	4.81	-0.13	-2.63%	4.94	4.94	4.77
Mar 28, 2024	4.94	0.10	2.07%	4.84	4.96	4.77
Mar 27, 2024	4.82	-0.08	-1.63%	4.90	4.93	4.80
Mar 26, 2024	4.87	0.04	0.83%	4.83	4.89	4.81
Mar 25, 2024	4.79	0.10	2.13%	4.69	4.87	4.68
Mar 22, 2024	4.77	-0.09	-1.85%	4.86	4.86	4.76
Mar 21, 2024	4.86	0.01	0.21%	4.85	4.95	4.85

Savara Events

Time (UTC)	Country	Event
Monday, May 13, 2024
Time (UTC) 12:30	Country US	Event Q1 2024 Savara Inc Earnings Release Q1 2024 Savara Inc Earnings Release Forecast - Previous -
Friday, June 7, 2024
Time (UTC) 19:00	Country US	Event Savara Inc Annual Shareholders Meeting Savara Inc Annual Shareholders Meeting Forecast - Previous -
Thursday, August 8, 2024
Time (UTC) 10:59	Country US	Event Q2 2024 Savara Inc Earnings Release Q2 2024 Savara Inc Earnings Release Forecast - Previous -

View all events

Annual
Quarterly

	2022	2021	2020	2019	2018
Total revenue	0	0	0.257	0	0
Revenue		0	0.257
Total Operating Expense	38.839	41.477	49.557	79.025	70.045
Selling/General/Admin. Expenses, Total	10.929	12.35	14.264	13.081	10.654
Research & Development	27.879	28.991	35.038	38.781	37.173
Depreciation / Amortization	0.031	0.136	0.255	0.311	0.526
Unusual Expense (Income)			0	26.852	21.692
Operating Income	-38.839	-41.477	-49.3	-79.025	-70.045
Interest Income (Expense), Net Non-Operating	-0.107	-2.381	-1.208	-0.361	0.018
Other, Net	0.796	0.844	0.893	1.213	1.454
Net Income Before Taxes	-38.15	-43.014	-49.615	-78.173	-68.573
Net Income After Taxes	-38.15	-43.014	-49.615	-78.173	-61.516
Net Income Before Extra. Items	-38.15	-43.014	-49.615	-78.173	-61.516
Net Income	-38.15	-43.014	-49.615	-78.173	-61.516
Income Available to Common Excl. Extra. Items	-38.15	-43.014	-49.615	-78.173	-61.516
Income Available to Common Incl. Extra. Items	-38.15	-43.014	-49.615	-78.173	-61.516
Diluted Net Income	-38.15	-43.014	-49.615	-78.173	-61.516
Diluted Weighted Average Shares	152.772	133.919	59.3091	40.0278	33.3007
Diluted EPS Excluding Extraordinary Items	-0.24972	-0.32119	-0.83655	-1.95297	-1.84729
Diluted Normalized EPS	-0.24972	-0.17185	-0.83655	-1.28214	-1.19589
Total Extraordinary Items
Total Adjustments to Net Income

	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022
Total revenue	0	0	0	0	0
Total Operating Expense	12.221	12.112	10.875	10.535	9.383
Selling/General/Admin. Expenses, Total	3.302	3.366	3.242	2.376	2.957
Research & Development	8.911	8.738	7.626	8.151	6.418
Depreciation / Amortization	0.008	0.008	0.007	0.008	0.008
Operating Income	-12.221	-12.112	-10.875	-10.535	-9.383
Interest Income (Expense), Net Non-Operating	0.742	0.794	0.574	0.144	-0.242
Other, Net	0.036	0.761	0.001	0.005	0.461
Net Income Before Taxes	-11.443	-10.557	-10.3	-10.386	-9.164
Net Income After Taxes	-11.443	-10.557	-10.3	-10.386	-9.164
Net Income Before Extra. Items	-11.443	-10.557	-10.3	-10.386	-9.164
Net Income	-11.443	-10.557	-10.3	-10.386	-9.164
Income Available to Common Excl. Extra. Items	-11.443	-10.557	-10.3	-10.386	-9.164
Income Available to Common Incl. Extra. Items	-11.443	-10.557	-10.3	-10.386	-9.164
Diluted Net Income	-11.443	-10.557	-10.3	-10.386	-9.164
Diluted Weighted Average Shares	152.797	152.782	152.773	152.773	152.771
Diluted EPS Excluding Extraordinary Items	-0.07489	-0.0691	-0.06742	-0.06798	-0.05999
Dividends per Share - Common Stock Primary Issue	0	0		0	0
Diluted Normalized EPS	-0.07489	-0.0691	-0.06742	-0.06798	-0.05999
Revenue

Annual
Quarterly

	2022	2021	2020	2019	2018
Total Current Assets	128.954	165	85.121	124.067	113.344
Cash and Short Term Investments	125.876	161.171	82.188	121.761	110.83
Cash & Equivalents	52.1	34.012	22.88	49.804	24.301
Total Receivables, Net	0.954	1.144	1.695	1.617	1.684
Prepaid Expenses	2.053	2.329	1.044	0.431	0.723
Other Current Assets, Total	0.071	0.356	0.194	0.258	0.107
Total Assets	139.777	176.598	97.745	136.203	152.287
Property/Plant/Equipment, Total - Net	0.151	0.373	0.356	1.025	0.522
Goodwill, Net					26.918
Intangibles, Net	10.656	11.274	12.218	11.111	11.372
Other Long Term Assets, Total	0.016	-0.049	0.05		0.131
Total Current Liabilities	5.867	14.66	8.174	10.88	7.254
Accounts Payable	1.334	1.443	2.595	3.409	3.879
Accrued Expenses	4.533	4.884	5.579	5.471	3.058
Notes Payable/Short Term Debt	0	0	0	0	0
Current Port. of LT Debt/Capital Leases	0	8.333		2	0.041
Total Liabilities	31.999	32.1	33.362	34.505	44.068
Total Long Term Debt	26.078	17.323	25.104	23.112	24.53
Long Term Debt	26.078	17.323	25.104	23.112	24.53
Capital Lease Obligations					0
Deferred Income Tax					0
Other Liabilities, Total	0.054	0.117	0.084	0.513	12.284
Total Equity	107.778	144.498	64.383	101.698	108.219
Preferred Stock - Non Redeemable, Net
Common Stock	0.116	0.116	0.055	0.052	0.036
Additional Paid-In Capital	446.938	444.898	320.893	309.555	237.702
Retained Earnings (Accumulated Deficit)	-338.671	-300.521	-257.507	-207.892	-129.719
Other Equity, Total	-0.594	0.054	0.942	-0.017	0.2
Total Liabilities & Shareholders’ Equity	139.777	176.598	97.745	136.203	152.287
Total Common Shares Outstanding	114.046	114.037	54.153	50.7904	35.1461
Total Preferred Shares Outstanding
Short Term Investments	73.776	127.159	59.308	71.957	86.529
Property/Plant/Equipment, Total - Gross	2.074	2.452	2.329	2.699	1.89
Accumulated Depreciation, Total	-1.923	-2.079	-1.973	-1.674	-1.368
Other Current Liabilities, Total				0	0.276
Unrealized Gain (Loss)	-0.011	-0.049

	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022
Total Current Assets	170.096	107.9	117.626	128.954	137.069
Cash and Short Term Investments	168.251	105.179	114.777	125.876	134.077
Cash & Equivalents	27.69	22.745	33.984	52.1	119.841
Short Term Investments	140.561	82.434	80.793	73.776	14.236
Total Receivables, Net	0.951	1.001	1.04	0.954	0.861
Prepaid Expenses	0.732	1.561	1.571	2.053	2.029
Other Current Assets, Total	0.162	0.159	0.238	0.071	0.102
Total Assets	182.072	119.833	129.359	139.777	147.758
Property/Plant/Equipment, Total - Net	0.277	0.264	0.047	0.051	0.059
Intangibles, Net	10.497	10.781	10.818	10.656	9.754
Other Long Term Assets, Total	1.202	0.888	0.868	0.116	0.876
Total Current Liabilities	8.963	5.885	4.922	5.867	5.163
Accounts Payable	3.219	2.502	1.573	1.334	0.893
Accrued Expenses	5.744	3.383	3.349	4.533	4.27
Notes Payable/Short Term Debt	0	0	0	0	0
Total Liabilities	35.528	32.118	31.104	31.999	31.244
Total Long Term Debt	26.281	26.213	26.145	26.078	26.01
Long Term Debt	26.281	26.213	26.145	26.078	26.01
Other Liabilities, Total	0.284	0.02	0.037	0.054	0.071
Total Equity	146.544	87.715	98.255	107.778	116.514
Common Stock	0.137	0.116	0.116	0.116	0.116
Additional Paid-In Capital	524.619	448.889	447.828	446.938	446.376
Retained Earnings (Accumulated Deficit)	-377.27	-360.671	-349.228	-338.671	-328.371
Unrealized Gain (Loss)	-0.062	-0.057	0.003	-0.011	-0.04
Other Equity, Total	-0.88	-0.562	-0.464	-0.594	-1.567
Total Liabilities & Shareholders’ Equity	182.072	119.833	129.359	139.777	147.758
Total Common Shares Outstanding	135.34	114.15	114.065	114.046	114.043
Current Port. of LT Debt/Capital Leases				0	0

Annual
Quarterly

	2022	2021	2020	2019	2018
Net income/Starting Line	-38.15	-43.014	-49.615	-78.173	-61.516
Cash From Operating Activities	-34.554	-40.081	-39.836	-45.123	-39.275
Cash From Operating Activities	0.031	0.136	0.255	1.01	0.526
Deferred Taxes					-7.057
Non-Cash Items	2.605	5.643	11.229	31.193	26.326
Cash Interest Paid	1.614	1.969	2.47	2.099	1.406
Changes in Working Capital	0.96	-2.846	-1.705	0.847	2.446
Cash From Investing Activities	52.645	-69.456	9.053	15.74	-13.619
Capital Expenditures	-0.009	-0.057	-3.294	-0.148	-0.141
Other Investing Cash Flow Items, Total	52.654	-69.399	12.347	15.888	-13.478
Cash From Financing Activities	0.087	120.806	3.689	54.908	55.193
Financing Cash Flow Items	-0.003	-0.078
Issuance (Retirement) of Stock, Net	0.002	120.884	4.203	54.949	46.374
Issuance (Retirement) of Debt, Net	0.088	0	-0.514	-0.041	8.819
Net Change in Cash	18.088	11.132	-26.924	25.503	2.18
Foreign Exchange Effects	-0.09	-0.137	0.17	-0.022	-0.119

	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
Net income/Starting Line	-10.557	-38.15	-27.85	-17.464	-8.3
Cash From Operating Activities	-12.026	-34.554	-25.903	-17.741	-8.425
Cash From Operating Activities	0.008	0.031	0.024	0.016	0.008
Non-Cash Items	-0.006	2.605	2.258	1.636	1.04
Cash Interest Paid	0.464	1.614	1.186	0.857	0.484
Changes in Working Capital	-1.471	0.96	-0.335	-1.929	-1.173
Cash From Investing Activities	-6.095	52.645	111.856	78.86	53.665
Capital Expenditures	-0.004	-0.009	-0.009	-0.005
Other Investing Cash Flow Items, Total	-6.091	52.654	111.865	78.865	53.665
Cash From Financing Activities	0.026	0.087	0.086	0.087	-0.001
Issuance (Retirement) of Stock, Net	0.027	0.002	0	0	0
Issuance (Retirement) of Debt, Net		0.088	0.088	0.088
Foreign Exchange Effects	-0.021	-0.09	-0.21	-0.065	-0.024
Net Change in Cash	-18.116	18.088	85.829	61.141	45.215
Financing Cash Flow Items	-0.001	-0.003	-0.002	-0.001	-0.001

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Savara Company profile

About Savara Inc

Savara Inc. is a clinical stage company. The Company is focused on rare respiratory diseases. The Company’s lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim an inhaled formulation of recombinant human GM-CSF, is being developed for the treatment of aPAP. Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the build-up of surfactant in the alveoli or air sacs of the lungs.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Savara Inc revenues decreased from $256K to $0K. Net loss decreased 12% to $31.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Research and development - Balancing val decrease of 13% to $20.4M (expense), Stock-based Compensation in SGA decrease of 51% to $1.5M (expense), Selling.

Equity composition

Common Stock $.001 Par, 12/11, 500M auth., 47,715,709 issd. Insiders own approx. 0.08% . IPO: N/A. PO: 11/02/06, 14,545,000 shs. @ $2.75 per share by ThinkEquity Partners LLC & Fortis Securities LLC. 04/10, 1-for-25 reverse split.

Industry:

Bio Therapeutic Drugs

6836 Bee Cave Road
Building 3, Suite 201
AUSTIN
TEXAS 78746
US

Income Statement

Annual
Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024